Real Madrid Extends Heartfelt Condolences to Barcelona After Doctor's Death
In a moment that transcends football rivalries, Real Madrid has extended its heartfelt condolences to FC Barcelona following the sudden passing of the club's first-team doctor, Carles Miñarro García. Also Read Ancelotti: Real Madrid Must Improve Before Atletico Clash
Miñarro tragically passed away just before Barcelona's scheduled La Liga match against Osasuna, prompting the Catalan club to request a postponement. Both La Liga and Osasuna supported the decision, allowing the team time to mourn.
The heartbreaking news has sent shockwaves through the football world, with tributes pouring in from clubs, players, and fans alike. Among those expressing sympathy is Barcelona's greatest rival, Real Madrid, which released an official statement offering its condolences. Real Madrid's Official Statement on Miñarro's Passing
The reigning Spanish champions expressed their sorrow and support in a message directed to Miñarro's family, teammates, and the entire Barcelona community.
"Real Madrid C.F., its president and board of directors express their deepest sadness at the death of FC Barcelona doctor, Carles Miñarro García."
"Real Madrid C. F. would like to express its condolences and sympathy to all his family, his teammates, FC Barcelona, and all his loved ones. Rest in peace."
Miñarro was a highly respected figure within Barcelona's dressing room, dedicating his career to the health and well-being of the players. His sudden passing has left a profound impact on the squad, with Barcelona president Joan Laporta delivering an emotional tribute.
Real Madrid's message of solidarity adds to the overwhelming wave of support from the footballing world, proving that some moments go beyond competition.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Bawaba
3 days ago
- Al Bawaba
Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an investigational, oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE). Although it did not meet the primary endpoint of dose-response relationship, when compared to placebo, enpatoran demonstrated improvements in measures of both systemic and cutaneous disease activity in prespecified SLE subpopulations despite standard of care (SoC), including those with active cutaneous manifestations at baseline [(CLASI-A) ≥8], and was overall well tolerated. These findings will be presented in a late-breaking oral presentation at the 2025 European Congress of Rheumatology (EULAR) in Barcelona (Abstract # LB0004). 'Analyses of Cohort B contribute to our understanding of enpatoran's potential to address the critical unmet needs for patients living with lupus, including those experiencing significant skin manifestations. These manifestations are often part of the systemic activity or flare, which can be painful and have a considerable impact on quality of life,' said principal investigator Prof. Eric Morand, from Monash University and Monash Health. 'The improvements observed in key disease measures represent a meaningful advancement in our ongoing investigation of the TLR7/8 inhibition approach for patients insufficiently managed by current therapies.' WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of oral enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus SoC over 24 weeks. The study features a unique design across two lupus cohorts, including both patients with active SLE and cutaneous lupus erythematosus (CLE). Cohort B of the study was designed to evaluate the dose-response relationship of enpatoran in reducing disease activity, based on the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response rate at Week 24 and enrolled SLE patients who had moderate or severe active disease despite SoC. Cohort B showed positive results in secondary and exploratory endpoints and within prespecified patient subpopulations. In patients with active skin disease (CLASI-A ≥8), BICLA response rates were up to 58.6% while placebo response rates were 31.7%, and up to 60.5% of patients receiving enpatoran showed a CLASI-70 response, compared with 26.8% for placebo, at Week 24. In addition, the subgroups of patients with high corticosteroid (prednisone-equivalent ≥10 mg/day) use and those with high interferon gene signature (IFN-GS) at baseline also showed higher and relevant BICLA response rates for enpatoran compared to placebo. As presented earlier this year at LUPUS 2025, Cohort A analyses from the WILLOW study showed clinically meaningful improvement in disease activity in patients with CLE and mild SLE with active lupus rash at Weeks 16 and 24. Overall, for skin-related signs and symptoms, comparable improvements were observed in Cohort B relative to Cohort A, reinforcing the potential efficacy of enpatoran in patients with cutaneous manifestations of lupus erythematosus with or without systemic disease. 'The efficacy and tolerability results from Cohort B, including among those with active skin involvement—a manifestation that affects most lupus patients—are consistent with our observations from Cohort A. The lupus rash is not only a visible symptom but is also closely linked to the underlying systemic activity of lupus,' said Jan Klatt, Head of Development Unit Neurology & Immunology for the Healthcare business of Merck. 'We are set to initiate regulatory discussions with key health authorities to determine the most effective pathway for bringing enpatoran to patients.' Enpatoran was well-tolerated and exhibited a manageable safety profile consistent with previous studies, with no new safety signals identified. Rates of treatment-emergent adverse events (TEAEs) were comparable between all enpatoran arms and placebo, ranging from 60.6% to 64.2%, and the most frequently reported TEAEs were infections and infestations. These results further support the anticipated favorable safety profile of enpatoran.
Al Bawaba
3 days ago
- Al Bawaba
Trent Alexander-Arnold to Wear Marcelo's Iconic No.12 Shirt at Real Madrid
Real Madrid are just hours away from officially presenting Trent Alexander-Arnold as their newest signing. The English full-back has already been registered in the club's squad list for the upcoming FIFA Club World Cup, and will be wearing the No.12 shirt. The number, once famously worn by club legend Marcelo, was most recently held by Eduardo Camavinga following the Brazilian's departure. According to Fabrizio Romano, the shirt now belongs to Alexander-Arnold as he begins the next chapter of his career in Spain. Leaving No.66 Behind At Liverpool, Alexander-Arnold was synonymous with the No.66 jersey—a number that started out randomly but eventually became a symbol of his rise through the ranks and his impact on the club. However, La Liga regulations prohibit players in the senior squad from wearing numbers higher than 25. This means Trent had no option but to adopt a new number—one that now carries the weight of legacy at the Santiago Bernabéu. Stepping into a Legacy The No.12 shirt isn't just available—it's loaded with meaning. Worn by Marcelo, arguably one of the greatest full-backs in Real Madrid history, the number has come to represent flair, longevity, and leadership from the back. For Alexander-Arnold, it's more than a jersey switch. It marks a new identity, a new challenge, and a significant shift in environment and expectation. The Premier League star will now look to make a name for himself in a squad built on history and silverware. Eyes on the Club World Cup Debut With Real Madrid's Club World Cup campaign on the horizon, fans may not have to wait long to see Trent in action. His debut is expected during the tournament. Swapping the familiar red of Anfield for the white of Madrid, and the No.66 for the legendary No.12, Trent Alexander-Arnold embarks on a journey that will define the next phase of his career. In a club where nothing short of excellence is accepted, Trent will be looking not just to follow in great footsteps—but to create his own.
Al Bawaba
6 days ago
- Al Bawaba
Cristiano Ronaldo: My son and Lamine Yamal look very much alike
ALBAWABA - Amid Portugal's victory against Spain in the UEFA Nations League finals, a new circulating report revealed that Cristiano Ronaldo said that Barcelona's golden boy, Lamine Yamal, looks a lot like his son. According to The Touchline, Ronaldo said, "My son and Lamine Yamal look very much alike, their skin colour, tan skin, their hairstyle... They are 3 years apart. I like Lamine Yamal a lot, and my son admires him a lot." The statement slammed the ongoing rumors claiming that the football stars clashed during the finals yesterday, after cameras captured Yamal's fierce look at Ronaldo. 🗣️ Cristiano Ronaldo: "My son and Lamine Yamal look very much alike, their skin colour, tan skin, their hairstyle... They are 3 years apart. I like Lamine Yamal a lot, and my son admires him a lot." — The Touchline | Football Coverage (@TouchlineX) June 7, 2025 At only 14 years old, Cristiano Ronaldo Jr. currently plays as a forward for Al-Nassr FC U15 in Saudi Arabia and recently made his debut for the Portugal U-15 national team. On the contrary, Lamine Yamal is considered Spain and Barcelona's upcoming golden boy at just 17 years old. He plays professionally for both teams. According to Goal, Yamal has garnered 18 goals and 25 assists across all competitions. However, while his performance across the board has been nothing but positive, Cristiano Ronaldo has urged the media and fans to keep expectations realistic for Yamal, reminding them he's still a kid with a long career ahead, setting a healthy example for future footballers, including his 14-year-old son.
